Get the Stockscreener App
28.12
1.48%
0.41
After Hours:
28.12
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences director sells $221,636 in stock - MSN
Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in Stock - Armenian Reporter
Castle Biosciences director sells $221,636 in stock By Investing.com - Investing.com Australia
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 - BioSpace
Castle Biosciences Earnings Alert: Key Financial Results Coming Feb 27Here's How to Listen In - StockTitan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Tritonpoint Wealth LLC - MarketBeat
Should You Bet on Castle Biosciences? The Truth Behind Its Stock Struggles! - Jomfruland.net
Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Vanguard Group Inc. Increases Stake in Castle Biosciences Inc. - GuruFocus.com
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet - Yahoo Finance
Leerink Partnrs Issues Optimistic Forecast for CSTL Earnings - Defense World
JPMorgan Chase & Co. Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
FY2024 Earnings Estimate for CSTL Issued By Leerink Partnrs - Defense World
Castle Biosciences (NASDAQ:CSTL) Trading 8.1% HigherTime to Buy? - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Buy" by Brokerages - MarketBeat
Castle Biosciences' DecisionDx-SCC Shows 92% Accuracy in Groundbreaking 1,400-Patient Cancer Study - StockTitan
Despite shrinking by US$214m in the past week, Castle Biosciences (NASDAQ:CSTL) shareholders are still up 29% over 1 year - Simply Wall St
Castle’s Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 - Yahoo Finance
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock - Investing.com India
Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock By Investing.com - Investing.com Australia
Castle Biosciences stock tumbles following guidance concerns - Investing.com India
Castle Biosciences stock tumbles following guidance concerns By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Trading Down 14%What's Next? - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Expects 50% Revenue Growth in 2024, Hits Record 96,000 Tests Despite Medicare Setback - StockTitan
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results - Milton Daily Standard
Harbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences stock falls following Medicare coverage denial By Investing.com - Investing.com Canada
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownHere's Why - MarketBeat
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 Shares - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 Shares - MarketBeat
Castle Biosciences' chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Canada
Castle Biosciences’ chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences director Bradbury sells shares worth $229,225 By Investing.com - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 - Investing.com India
Castle Biosciences director Bradbury sells shares worth $229,225 - Investing.com
Castle Biosciences' chief commercial officer sells $66,900 in shares - Investing.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Up 6.2%Here's Why - MarketBeat
Castle Biosciences gains NY approval for esophageal test By Investing.com - Investing.com Nigeria
1.05%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):